Latest Biotech News

NanoMosaic and Solid Biosciences moved to co-market and technically align their gene therapy workflow tools, targeting AAV vector development and manufacturing analytics. The deal pairs...

A portable bedside PET scanner technology was presented as a new option for real-time imaging during interventional procedures. Researchers at Washington University in St. Louis described a...

A new licensing push highlighted Lilly’s continued expansion in GLP biology with a $75 million upfront deal for Hanmi’s long-acting GLP-2 analog sonefpeglutide. Lilly secured exclusive worldwide...

Abivax’s Phase 3 ulcerative colitis maintenance readout showed strong efficacy, but the stock moved sharply lower after malignancy cases emerged among treatment recipients. In the Abtect trial,...

The FDA approved Foundation Medicine’s FoundationOne CDx assay as a companion diagnostic to identify patients for Pfizer’s Talzenna plus Xtandi regimen in HRR-mutated metastatic...

Anti-aging startup NewLimit raised $435 million at a valuation above $3 billion in a Series C financing led by Founders Fund. The company said it expects to start human testing next year for its...

The FDA released additional CBER draft guidance detailing how cell and gene therapy developers can leverage prior knowledge. The agency outlined the types of information companies may reuse across...

Evosep and Molecular You announced a partnership intended to standardize high-throughput multiomic biomarker testing workflows. The collaboration integrates Evosep’s Eno liquid chromatography...

NanoMosaic and Solid Biosciences announced a comarketing agreement focused on improving AAV manufacturing analytics for gene therapy developers. NanoMosaic will promote its Tessie automated plate...

Servier will acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65 billion, including $1.55 billion upfront and as much as $1.1 billion tied to regulatory and...

Travere Therapeutics is stepping up its rare kidney disease pipeline by paying Everest Medicines $112.5 million upfront for a drug program targeting a broader set of rare kidney indications beyond...

Autobahn Therapeutics received FDA Fast Track designation for elunetirom (ABX-002) as an adjunctive treatment for depressive episodes in adults with bipolar I or bipolar II disorder. The...

Akeso’s ivonescimab delivered a statistically significant overall survival improvement in a Phase 3 lung cancer regimen presented at ASCO. In interim data from the Harmoni-6 trial in China,...

The FDA approved Foundation Medicine’s FoundationOne CDx assays as companion diagnostics for Pfizer’s Talzenna plus Xtandi regimen in metastatic castration-resistant prostate cancer with...

Voyager Therapeutics received FDA IND clearance for VY-1706, an investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease. The company’s IND path indicates...

Iovance Biotherapeutics received FDA IND clearance for IOV-5001, a next-generation tumor-infiltrating lymphocyte (TIL) therapy engineered with an interleukin-12 (IL-12) tethering component. The...

French researchers at Eligo Bioscience and collaborators published results on EB-003, a CRISPR-based antimicrobial approach targeting Shiga toxin-producing E. coli (STEC). The strategy comes amid...

Veracyte launched Prosigna Breast Risk of Recurrence as a laboratory-developed test (LDT) in the US after ASCO data suggested the assay can safely guide adjuvant treatment decisions for patients...

The FDA approved new Foundation Medicine companion diagnostics tied to Pfizer’s prostate cancer regimen, extending the clinical footprint of FoundationOne CDx as a decision tool for specific...

Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy business in a transaction valued at up to $2.65 billion, betting that neuromuscular franchise scale can accelerate its neurology...